| P2093 | author name string | E Mozes | |
| | M Dayan | |
| | Z Sthoeger | |
| | A Tcherniack | |
| | A Faber-Elmann | |
| P2860 | cites work | Molecular characterization of a low-molecular-mass matrix metalloproteinase secreted by glomerular mesangial cells as PUMP-1 | Q28115921 |
| | Matrix metalloproteinases: structures, evolution, and diversification | Q28282370 |
| | Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications | Q33692926 |
| | Tumour necrosis factor and other cytokines in murine lupus | Q33782338 |
| | Cytokines and systemic lupus erythematosus | Q33873329 |
| | The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus | Q34649237 |
| | Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases | Q35824305 |
| | Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis | Q35831850 |
| | Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid | Q36401533 |
| | Progesterone regulates the activity of collagenase and related gelatinases A and B in human endometrial explants | Q37339407 |
| | Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy | Q37352123 |
| | Matrix metalloproteinases in immunity. | Q40968642 |
| | Collagenase: a key enzyme in collagen turnover | Q41481774 |
| | The role of metalloproteinases and their inhibitors in hematological disorders. | Q41564124 |
| | Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor | Q41839052 |
| | Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2. | Q42495609 |
| | TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. | Q42526214 |
| | Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. | Q44441787 |
| | Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. | Q47677906 |
| | Metalloproteinases and their tissue inhibitors in multiple sclerosis. | Q48208945 |
| | Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders | Q48416379 |
| | Matrix metalloproteinase expression during experimental autoimmune neuritis | Q48486731 |
| | Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. | Q50862383 |
| | The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. | Q52884043 |
| | Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate mark | Q52980619 |
| | The matrix metalloproteinase inhibitor BB-1101 prevents experimental autoimmune uveoretinitis (EAU). | Q53939274 |
| | Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases | Q57584769 |
| | Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity | Q59032064 |
| | Processing of tumour necrosis factor-α precursor by metalloproteinases | Q59059630 |
| | Human pleural effusions are rich in matrix metalloproteinases | Q67589511 |
| | Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression | Q67672646 |
| | Gene expression of metalloproteinases and their inhibitor in renal tissue of New Zealand black/white F1 mice | Q70490477 |
| | Effect of oral adsorbent AST-120 on plasma metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 concentrations in chronic renal failure | Q73071615 |
| | Hormonal regulation of matrix metalloproteinase 9/gelatinase B gene expression in rabbit uterine cervical fibroblasts | Q73103450 |
| | Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease | Q73128692 |
| | Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barré syndrome | Q73187372 |
| | Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis | Q73197327 |
| | Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms | Q77319343 |
| | Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis | Q77434334 |
| P433 | issue | 2 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| P304 | page(s) | 393-398 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | Clinical and Experimental Immunology | Q15716708 |
| P1476 | title | Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus | |
| P478 | volume | 127 | |